相关实验视频
Updated: Sep 14, 2025
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.1K
通过皮肤冠状动脉干预后发生的严重的铁洛菲班诱导的血小板缺血
John M Sousou1, Kabeer Ali1, Melville C O'Brien1
1Internal Medicine, University of Florida College of Medicine - Jacksonville, Jacksonville, FL, USA.
Journal of cardiology cases
|July 23, 2025
概括
铁洛非班是一种糖蛋白IIb/IIIa抑制剂,可在急性冠状动脉综合征患者中引起罕见但严重的血小板缺血. 早期监测血小板数量对于预防严重出血或血栓事件至关重要.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学 是一个学科.
- 血液学 血液学 血液学
背景情况:
- 蒂罗菲班是一种静脉注射的葡萄糖蛋白IIb/IIIa抑制剂,用于急性冠状动脉综合征 (ACS) 患有高血栓负担,经过皮肤冠状动脉干预 (PCI).
- 严重的血小板缺血是一种罕见但严重的蒂罗菲班并发症,发生在0.1-0.5%的患者中.
研究的目的:
- 在接受PCI的ACS患者中,在提洛菲班给药后出现严重的血小板缩病例.
- 强调早期识别和治疗铁奥菲班诱导的血小板缺血的重要性.
- 突出需要在接受糖蛋白IIb/IIIa抑制剂的患者中进行常规血小板监测.
主要方法:
- 一个患有ACS的患者的病例报告呈现,该患者在tirofiban后发展出严重的血小板缺血症.
- 审查的病理生理学和临床表现的tirofiban诱导的血小板缺血症.
- 讨论管理策略,包括戒毒,监测和支持性护理.
主要成果:
- 患者在接受tirofiban后24小时内出现严重的血小板缺血.
- 蒂罗菲班诱导的血小板缺血是一种免疫媒介的疾病,增加了出血风险.
- 治疗包括立即停止使用药物和密切监测血小板数量.
结论:
- 早期识别和血小板计数的监测对于接受tirofiban的患者至关重要.
- 及时识别和管理提洛菲班诱导的血小板缺血症可以预防严重的不良后果.
- 这一案例强调了对心血管医学中罕见但严重的药物并发症的警的重要性.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
23
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
23
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
45
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
45
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
648
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
648
01:28Acute Coronary Syndrome IV: Interprofessional Care
30
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
30
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
913
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
913
01:30Acute Coronary Syndrome I: Introduction
80
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
80